SUCRALFATE

Post-LOE

sucralfate oral suspension

KalVista Pharmaceuticals
ANDAORALSUSPENSION
Approved
Mar 2022
Lifecycle
Post-LOE
Competitive Pressure
30/100

Mechanism of Action

Pharmacologic Class:

Aluminum Complex

Company
KalVista Pharmaceuticals
KalVista Pharmaceuticals
FRAMINGHAM, MA
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers